Table 2. Case fatality rates by stage on June 30, 2020, in women with high-grade serous tubo-ovarian cancer diagnosed between randomisation and Dec 31, 2014.
| No screening group (clinically diagnosed) | Multimodal screening group | Ultrasound screening group | ||||||
|---|---|---|---|---|---|---|---|---|
| Screen detected | Clinically diagnosed | Total | Screen detected | Clinically diagnosed | Total | |||
| FIGO 2014 Stage | ||||||||
| I | 16/34 (47%) | 13/27 (48%) | 5/10 (50%) | ·· | 2/11 (18%) | 4/7 (57%) | ·· | |
| II | 22/40 (55%) | 9/19 (47%) | 5/8 (63%) | ·· | 4/10 (40%) | 2/8 (25%) | ·· | |
| III | 294/325 (90%) | 86/95 (91%) | 53/61 (87%) | ·· | 48/53 (91%) | 92/102 (90%) | ·· | |
| IV | 111/118 (94%) | 12/12 (100%) | 21/26 (81%) | ·· | 7/7 (100%) | 48/52 (92%) | ·· | |
| Unable to stage | 3/3 (100%) | 0 | 1/1 (100%) | ·· | 0 | 0 | ·· | |
| Total by screening status | 446/520 (86%) | 120/153 (78%) | 85/106 (80%) | ·· | 61/81 (75%) | 146/169 (86%) | ·· | |
| Total by intention to screen | 446/520 (86%) | ·· | ·· | 205/259 (79%) | ·· | ·· | 207/250 (83%) | |
Data are n/N (%). Median follow-up (years) from randomisation: no screening 9·5 (IQR 5·1–12·6); multimodal screening –9·7 (IQR 6·2–14·1); and ultrasound screening 9·4 (IQR 6·1–12·9).